133 related articles for article (PubMed ID: 38353416)
1. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Boussen I; Salmona M; Sicre De Fontbrune F; Xhaard A; De Castro N; Delaugerre C; Chaix ML; Molina JM
Antivir Ther; 2024 Feb; 29(1):13596535221097495. PubMed ID: 38353416
[TBL] [Abstract][Full Text] [Related]
2. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Peiffer-Smadja N; Bridier-Nahmias A; Ferré VM; Charpentier C; Garé M; Rioux C; Allemand A; Lavallée P; Ghosn J; Kramer L; Descamps D; Yazdanpanah Y; Visseaux B
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452507
[TBL] [Abstract][Full Text] [Related]
3. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
4. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
5. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
6. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.
Sabin AP; Richmond CS; Kenny PA
Diagn Microbiol Infect Dis; 2022 May; 103(1):115656. PubMed ID: 35231807
[TBL] [Abstract][Full Text] [Related]
7. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
8. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
Widera M; Wilhelm A; Hoehl S; Pallas C; Kohmer N; Wolf T; Rabenau HF; Corman VM; Drosten C; Vehreschild MJGT; Goetsch U; Gottschalk R; Ciesek S
J Infect Dis; 2021 Oct; 224(7):1109-1114. PubMed ID: 34223909
[TBL] [Abstract][Full Text] [Related]
9. Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.
Lohr B; Niemann D; Verheyen J
Clin Infect Dis; 2021 Dec; 73(11):2144-2145. PubMed ID: 34009286
[No Abstract] [Full Text] [Related]
10. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
[TBL] [Abstract][Full Text] [Related]
11. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
Sims JT; Poorbaugh J; Chang CY; Holzer TR; Zhang L; Engle SM; Beasley S; Doman TN; Naughton L; Higgs RE; Kallewaard N; Benschop RJ
J Transl Med; 2022 Mar; 20(1):134. PubMed ID: 35303909
[TBL] [Abstract][Full Text] [Related]
12. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
Yetmar ZA; Yao JD; Razonable RR
J Med Virol; 2023 Jun; 95(6):e28885. PubMed ID: 37334976
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
[TBL] [Abstract][Full Text] [Related]
16. Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.
Bachmann F; Budde K; Suttorp N; Lingscheid T; Stegemann MS; Osmanodja B; Schrezenmeier E; Duettmann W; Weber U; Naik M; Lehner LJ; Kahl A; Duerr M; Eckardt KU; Waiser J; Choi M; Halleck F
Transpl Int; 2022; 35():10109. PubMed ID: 35431640
[No Abstract] [Full Text] [Related]
17. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
19. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Benschop RJ; Tuttle JL; Zhang L; Poorbaugh J; Kallewaard NL; Vaillancourt P; Crisp M; Trinh TNV; Freitas JJ; Beasley S; Daniels M; Haustrup N; Higgs RE; Nirula A; Cohen MS; Marovich M
Sci Transl Med; 2022 Jul; 14(655):eabn3041. PubMed ID: 35679357
[TBL] [Abstract][Full Text] [Related]
20. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
Chatterjee S; Choudhury S; Das D
Indian J Pharmacol; 2022; 54(1):51-57. PubMed ID: 35343208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
